Table 3.
SGLT2i trials in renal disease.
| Trial (Medication) |
Main Outcome HR (95% CI) (p-Value) |
Key Summary |
|---|---|---|
| CREDENCE [21] (canagliflozin 100 mg) |
↓ ESRD, doubling of sCr, renal death, or CV death 0.70 (0.59–0.82) (p = 0.00001) |
CREDENCE was the first trial in more than two decades in improving kidney endpoints. |
| DAPA-CKD [22] (dapagliflozin 10 mg) |
↓ Decline in eGFR, new ESRD, renal death, or CV death 0.61 (0.51–0.72) (p < 0.001) |
Dapagliflozin reduced the risk of eGFR decline, ESRD, and renal or CV death in CKD patients, regardless of diabetic status. |
| EMPA-KIDNEY [24] (empagliflozin 10 mg) |
↓ ESRD, decrease in eGFR, renal death or CV death 0.72 (0.64–0.82) (p < 0.001) ↓ Hospitalization 0.86 (0.78–0.95) (p = 0.003) |
Empagliflozin reduced ESRD, eGFR decline, and renal or CV death in CKD patients, regardless of diabetic status. |
CKD, chronic kidney disease; CV, cardiovascular; eGFR, estimated glomerular filtration rate; ESRD, end-stage renal disease; GLD, glucose lowering drugs; sCr, serum creatinine.